Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Current Assets: 2019-2024

Historic Current Assets for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to $278.4 million.

  • Pharming Group N.V's Current Assets fell 1.63% to $277.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $277.6 million, marking a year-over-year decrease of 1.63%. This contributed to the annual value of $278.4 million for FY2024, which is 11.98% down from last year.
  • Latest data reveals that Pharming Group N.V reported Current Assets of $278.4 million as of FY2024, which was down 11.98% from $316.3 million recorded in FY2023.
  • In the past 5 years, Pharming Group N.V's Current Assets ranged from a high of $316.3 million in FY2023 and a low of $249.4 million during FY2021.
  • In the last 3 years, Pharming Group N.V's Current Assets had a median value of $278.4 million in 2024 and averaged $290.8 million.
  • As far as peak fluctuations go, Pharming Group N.V's Current Assets skyrocketed by 120.38% in 2020, and later declined by 11.98% in 2024.
  • Yearly analysis of 5 years shows Pharming Group N.V's Current Assets stood at $263.2 million in 2020, then dropped by 5.23% to $249.4 million in 2021, then grew by 11.25% to $277.5 million in 2022, then grew by 14.00% to $316.3 million in 2023, then decreased by 11.98% to $278.4 million in 2024.